Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have earned an average recommendation of “Hold” from the eleven research firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $27.80.
A number of analysts have issued reports on the stock. Nomura reiterated a “buy” rating and issued a $37.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, August 13th. BidaskClub cut shares of Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 27th. Zacks Investment Research cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 9th. Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, November 6th. Finally, Morgan Stanley reduced their target price on shares of Voyager Therapeutics from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Friday, October 11th.
Large investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new position in shares of Voyager Therapeutics in the second quarter valued at approximately $27,000. NumerixS Investment Technologies Inc bought a new position in shares of Voyager Therapeutics in the second quarter valued at approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Voyager Therapeutics by 371.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,126 shares of the company’s stock valued at $58,000 after purchasing an additional 1,675 shares during the period. HM Payson & Co. bought a new position in shares of Voyager Therapeutics in the second quarter valued at approximately $63,000. Finally, Bank of Montreal Can raised its position in shares of Voyager Therapeutics by 244.1% in the second quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock valued at $76,000 after purchasing an additional 1,994 shares during the period. 78.62% of the stock is currently owned by institutional investors.
Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Wednesday, November 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.42. The firm had revenue of $20.43 million during the quarter, compared to analysts’ expectations of $3.94 million. Voyager Therapeutics had a negative net margin of 72.64% and a negative return on equity of 57.32%. On average, equities analysts predict that Voyager Therapeutics will post -1.6 earnings per share for the current year.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Featured Article: Penny Stocks
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.